IQVIA HOLDINGS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
IQVIA HOLDINGS INC. (IQV) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $16.77 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-12.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2015-02-12
- IQVIA HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2014 was $16.77M, a 31.10% increase from fiscal 2013.
- IQVIA HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2013 was $12.79M, a 25.20% decline from fiscal 2012.
- IQVIA HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2012 was $17.10M, a 21.15% increase from fiscal 2011.
- IQVIA HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2011 was $14.11M.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2014-12-31 | $16.77M 10-K · filed 2015-02-12 |
| 2013-12-31 | $12.79M 10-K · filed 2015-02-12 |
| 2012-12-31 | $17.10M 10-K · filed 2015-02-12 |
| 2011-12-31 | $14.11M 10-K · filed 2014-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B |